steady-state in patients [Design Issues]

posted by qualityassurance – 2025-01-09 11:59 (75 d 05:05 ago) – Posting: # 24334
Views: 716

Hi Helmut,

Recently a paper1 is published which shows Novonordisk conducted steady state study to prove BE between different strengths (3 mg, 7 mg , 14 mg vs 1.5 mg, 4 mg, 9 mg) of semaglutide tablets and EMA accepted it. As a generic company can we use the same approach for EMA?

Regards,
QA

1 https://link.springer.com/article/10.1007/s13300-024-01674-8

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,714 registered users;
21 visitors (0 registered, 21 guests [including 5 identified bots]).
Forum time: 17:05 CET (Europe/Vienna)

It’s easy to lie with statistics;
it is easier to lie without them.    Frederick Mosteller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5